Browsing by Author "Kumar, Manoj"

Now showing 1 - 8 of 8
  • No Thumbnail Available
    Item
    Alzheimer's disease: Molecular aspects and treatment opportunities using herbal drugs
    (Elsevier Ireland Ltd, 2023-05-22T00:00:00) Thakral, Samridhi; Yadav, Alka; Singh, Vikramjeet; Kumar, Manoj; Kumar, Pradeep; Narang, Rakesh; Sudhakar, Kalvatala; Verma, Amita; Khalilullah, Habibullah; Jaremko, Mariusz; Emwas, Abdul-Hamid
    Alzheimer's disease (AD), also called senile dementia, is the most common neurological disorder. Around 50 million people, mostly of advanced age, are suffering from dementia worldwide and this is expected to reach 100�130 million between 2040 and 2050. AD is characterized by impaired glutamatergic and cholinergic neurotransmission, which is associated with clinical and pathological symptoms. AD is characterized clinically by loss of cognition and memory impairment and pathologically by senile plaques formed by Amyloid ? deposits or neurofibrillary tangles (NFT) consisting of aggregated tau proteins. Amyloid ? deposits are responsible for glutamatergic dysfunction that develops NMDA dependent Ca2+ influx into postsynaptic neurons generating slow excitotoxicity process leading to oxidative stress and finally impaired cognition and neuronal loss. Amyloid decreases acetylcholine release, synthesis and neuronal transport. The decreased levels of neurotransmitter acetylcholine, neuronal loss, tau aggregation, amyloid ? plaques, increased oxidative stress, neuroinflammation, bio-metal dyshomeostasis, autophagy, cell cycle dysregulation, mitochondrial dysfunction, and endoplasmic reticulum dysfunction are the factors responsible for the pathogenesis of AD. Acetylcholinesterase, NMDA, Glutamate, BACE1, 5HT6, and RAGE (Receptors for Advanced Glycation End products) are receptors targeted in treatment of AD. The FDA approved acetylcholinesterase inhibitors Donepezil, Galantamine and Rivastigmine and N-methyl-D-aspartate antagonist Memantine provide symptomatic relief. Different therapies such as amyloid ? therapies, tau-based therapies, neurotransmitter-based therapies, autophagy-based therapies, multi-target therapeutic strategies, and gene therapy modify the natural course of the disease. Herbal and food intake is also important as preventive strategy and recently focus has also been placed on herbal drugs for treatment. This review focuses on the molecular aspects, pathogenesis and recent studies that signifies the potential of medicinal plants and their extracts or chemical constituents for the treatment of degenerative symptoms related to AD. � 2023 Elsevier B.V.
  • No Thumbnail Available
    Item
    Ampelopsin targets in cellular processes of cancer: Recent trends and advances
    (Elsevier Inc., 2022-07-27T00:00:00) Tuli, Hardeep Singh; Sak, Katrin; Garg, Vivek Kumar; Kumar, Ajay; Adhikary, Shubham; Kaur, Ginpreet; Parashar, Nidarshana Chaturvedi; Parashar, Gaurav; Mukherjee, Tapan Kumar; Sharma, Uttam; Jain, Aklank; Mohapatra, Ranjan K.; Dhama, Kuldeep; Kumar, Manoj; Singh, Tejveer
    Cancer is being considered as a serious threat to human health globally due to limited availability and efficacy of therapeutics. In addition, existing chemotherapeutic drugs possess a diverse range of toxic side effects. Therefore, more research is welcomed to investigate the chemo-preventive action of plant-based metabolites. Ampelopsin (dihydromyricetin) is one among the biologically active plant-based chemicals with promising anti-cancer actions. It modulates the expression of various cellular molecules that are involved in cancer progressions. For instance, ampelopsin enhances the expression of apoptosis inducing proteins. It regulates the expression of angiogenic and metastatic proteins to inhibit tumor growth. Expression of inflammatory markers has also been found to be suppressed by ampelopsin in cancer cells. The present review article describes various anti-tumor cellular targets of ampelopsin at a single podium which will help the researchers to understand mechanistic insight of this phytochemical. � 2022 The Authors
  • No Thumbnail Available
    Item
    Determinants for macromolecular crowding-induced thermodynamic stabilization of acid-denatured cytochrome c to molten globules
    (Elsevier B.V., 2023-07-22T00:00:00) Kumari, Beeta; Shabnam; Yadav, Manisha; Kumar, Manoj; Kushwaha, Pratibha; Prakash Prabhu, N.; Kumar, Rajesh
    The macromolecular crowding effect transforms the acid-denatured ferricytochrome c (cyt cIII) (UA-state) to molten-globule (MGMC-state) at pH 1.85. Crowding-induced stabilization free energy (??G) and preferential hydration ??W were estimated for the UA ? MGMC transition. The magnitudes of ??G and ??W were found to be decreased as dextran 70 (D70) > dextran 40 (D40) > ficoll 70 (F70), which demonstrates that ??G and ??W track the molecular size and shape of the crowder towards refolding and stabilization of UA-state to MGMC-state. Analysis of effects of crowders (D40, D70, F70) on thermal and chemical-denaturations of acid-denatured cyt cIII provided several important information, (i) macromolecular crowding increased the thermodynamic stability of acid-denatured cyt cIII, (ii) concentration, size and shape of crowder control the crowding-induced thermodynamic stabilization of MGMC-state, (iii) crowding effect increased the thermal-denaturation midpoint (Tm) with a slight change in enthalpy (?Hm), suggesting that the steric-excluded volume effect contributes to the crowding-induced increased thermal stability of the acid-denatured protein. Analysis of entropy ? enthalpy plots for D40, D70, and F70 reveals that in addition to the steric-excluded volume effect, the enthalpic contribution is also added to the macromolecular crowding-induced stabilization of acid-denatured cyt cIII. The dilute-medium, compound-crowder, purely entropic-crowder and purely enthalpic-crowder curves were obtained for acid-denatured cyt cIII for D70, D40 and F70. The crossover temperature, Tx was calculated from the dilute and compound-crowder curves. The Tx values measured for D40, D70, and F70 were found to be ? 250.15 K, 272.15 K, and 275.15 K, respectively, which suggests that the Tx value depends on the size and shape of the crowder. Furthermore, the observation of a lower value of Tx and a minor enthalpic component for D40, D70, and F70 is likely due to the formation of weaker soft interactions of acid-denatured cyt cIII with D40, D70, and F70. � 2023 Elsevier B.V.
  • No Thumbnail Available
    Item
    Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
    (MDPI, 2022-11-08T00:00:00) Singh Tuli, Hardeep; Kumar, Ajay; Ramniwas, Seema; Coudhary, Renuka; Aggarwal, Diwakar; Kumar, Manoj; Sharma, Ujjawal; Chaturvedi Parashar, Nidarshana; Haque, Shafiul; Sak, Katrin
    Despite the immense therapeutic advances in the field of health sciences, cancer is still to be found among the global leading causes of morbidity and mortality. Ethnomedicinally, natural bioactive compounds isolated from various plant sources have been used for the treatment of several cancer types and have gained notable attention. Ferulic acid, a natural compound derived from various seeds, nuts, leaves, and fruits, exhibits a variety of pharmacological effects in cancer, including its proapoptotic, cell-cycle-arresting, anti-metastatic, and anti-inflammatory activities. This review study presents a thorough overview of the molecular targets and cellular signaling pathways modulated by ferulic acid in diverse malignancies, showing high potential for this phenolic acid to be developed as a candidate agent for novel anticancer therapeutics. In addition, current investigations to develop promising synergistic formulations are also discussed. � 2022 by the authors.
  • No Thumbnail Available
    Item
    Galangin: A metabolite that suppresses anti-neoplastic activities through modulation of oncogenic targets
    (SAGE Publications Inc., 2021-12-14T00:00:00) Tuli, Hardeep Singh; Sak, Katrin; Adhikary, Shubham; Kaur, Ginpreet; Aggarwal, Diwakar; Kaur, Jagjit; Kumar, Manoj; Parashar, Nidarshana Chaturvedi; Parashar, Gaurav; Sharma, Uttam; Jain, Aklank
    With the dramatic increase in cancer incidence all over the world in the last decades, studies on identifying novel efficient anti-cancer agents have been intensified. Historically, natural products have represented one of the most important sources of new lead compounds with a wide range of biological activities. In this article, the multifaceted anti-cancer action of propolis-derived flavonoid, galangin, is presented, discussing its antioxidant, anti-inflammatory, antiproliferative, pro-apoptotic, anti-angiogenic, and anti-metastatic effects in various cancer cells. In addition, co-effects with standard chemotherapeutic drugs as well as other natural compounds are also under discussion, besides highlighting modern nanotechnological advancements for overcoming the low bioavailability issue characteristic of galangin. Although further studies are needed for confirming the anti-cancer potential of galangin in vivo malignant systems, exploring this natural compound might open new perspectives in molecular oncology. � 2021 by the Society for Experimental Biology and Medicine.
  • No Thumbnail Available
    Item
    Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives
    (MDPI, 2022-11-01T00:00:00) Singh Tuli, Hardeep; Rath, Prangya; Chauhan, Abhishek; Sak, Katrin; Aggarwal, Diwakar; Choudhary, Renuka; Sharma, Ujjawal; Vashishth, Kanupriya; Sharma, Sheetu; Kumar, Manoj; Yadav, Vikas; Singh, Tejveer; Yerer, Mukerrem Betul; Haque, Shafiul
    Increasing rates of cancer incidence and the toxicity concerns of existing chemotherapeutic agents have intensified the research to explore more alternative routes to combat tumor. Luteolin, a flavone found in numerous fruits, vegetables, and herbs, has exhibited a number of biological activities, such as anticancer and anti-inflammatory. Luteolin inhibits tumor growth by targeting cellular processes such as apoptosis, cell-cycle progression, angiogenesis and migration. Mechanistically, luteolin causes cell death by downregulating Akt, PLK-1, cyclin-B1, cyclin-A, CDC-2, CDK-2, Bcl-2, and Bcl-xL, while upregulating BAX, caspase-3, and p21. It has also been reported to inhibit STAT3 signaling by the suppression of STAT3 activation and enhanced STAT3 protein degradation in various cancer cells. Therefore, extensive studies on the anticancer properties of luteolin reveal its promising role in chemoprevention. The present review describes all the possible cellular interactions of luteolin in cancer, along with its synergistic mode of action and nanodelivery insight. � 2022 by the authors.
  • No Thumbnail Available
    Item
    Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance
    (Academic Press, 2020-10-29T00:00:00) Tuli, Hardeep Singh; Mittal, Sonam; Aggarwal, Diwakar; Parashar, Gaurav; Parashar, Nidarshana Chaturvedi; Upadhyay, Sushil Kumar; Barwal, Tushar Singh; Jain, Aklank; Kaur, Ginpreet; Savla, Raj; Sak, Katrin; Kumar, Manoj; Varol, Mehmet; Iqubal, Ashif; Sharma, Anil Kumar
    In the last few decades, targeting cancer by the use of dietary phytochemicals has gained enormous attention. The plausible reason and believe or mind set behind this fact is attributed to either lesser or no side effects of natural compounds as compared to the modern chemotherapeutics, or due to their conventional use as dietary components by mankind for thousands of years. Silibinin is a naturally derived polyphenol (a flavonolignans), possess following biochemical features; molecular formula C25H22O10, Molar mass: 482.44 g/mol, Boiling point 793 �C, with strikingly high antioxidant and anti-tumorigenic properties. The anti-cancer properties of Silibinin are determined by a variety of cellular pathways which include induction of apoptosis, cell cycle arrest, inhibition of angiogenesis and metastasis. In addition, Silibinin controls modulation of the expression of aberrant miRNAs, inflammatory response, and synergism with existing anti-cancer drugs. Therefore, modulation of a vast array of cellular responses and homeostatic aspects makes Silibinin an attractive chemotherapeutic agent. However, like other polyphenols, the major hurdle to declare Silibinin a translational chemotherapeutic agent, is its lesser bioavailability. After summarizing the chemistry and metabolic aspects of Silibinin, this extensive review focuses on functional aspects governed by Silibinin in chemoprevention with an ultimate goal of summarizing the evidence supporting the chemopreventive potential of Silibinin and clinical trials that are currently ongoing, at a single platform. � 2020 Elsevier Ltd
  • No Thumbnail Available
    Item
    Rational design and synthesis of novel biphenyl thiazolidinedione conjugates as inhibitors of protein tyrosine phosphatase 1B for the management of type 2 diabetes
    (Elsevier B.V., 2022-11-12T00:00:00) Thareja, Suresh; Verma, Sant Kumar; Jain, Akhlesh Kumar; Kumar, Manoj; Bhardwaj, Tilak Raj
    To achieve the unmet discovery of protein tyrosine phosphatase 1B (PTP1B) inhibitors, we have rationally designed novel biphenyl thiazolidinedione conjugates (8a-n). The designed molecules were found fit on in silico absorption, distribution, metabolism, excretion, and toxicity (ADMET) screening criteria of drug-likeness. Ligand-target binding study revealed that N-methyl benzoic acid derivative (8j) was best target fit and displayed extended plausible binding interactions with phospho-tyrosine (pTyr) loop of PTP1B, a unique bidentate binding mode for PTP1B selectivity over other PTPs. The designed analogues (8a-n) were synthesized (Scheme 1) and accessed for their in vitro PTP1B inhibitory potency, in vivo anti-hyperglycemic efficacy as well as the effect of treatment on weight and pancreatic safety. Molecules 8a-n showed moderate to good PTP1B inhibitory activity (IC50 = 5.897�48.150 �M) compared to Suramin (IC50 = 11.104 �M) and exhibited time-dependent in vivo efficacy, ranging from inferior to better, as compared to Pioglitazone. Moreover, 8j was found best pre-clinical candidate exhibiting good in vitro potency (IC50 = 5.897 �M), better in vivo efficacy with the advantage of control in weight and pancreatic safety, compared to glitazone therapy. � 2022 Elsevier B.V.